Meyka Pro is live. Get 50% off your first 3 months.Get Started →
Meyka Pro banner
ImmunityBio, Inc.

ImmunityBio, Inc. (IBRX) Stock Overview

Explore ImmunityBio, Inc.’s financial performance, market position, analyst ratings, and future outlook.

IBRX●NASDAQ
HealthcareBiotechnology
$10.29
$1.010(10.88%)
U.S. Market opens in 0h 24m

ImmunityBio, Inc. (IBRX)

Meyka AI Score

Z

Key Financials

Market Cap10.8B
P/E Ratio-10.40
EPS (TTM)$-0.97
ROE1.35%
Fundamental Analysis

AI Price Forecasts

1 Month$8.80
3 Months$8.58
1 Year Target$7.34

IBRX Stock Analysis & Investment Overview (NASDAQ)

Our AI-powered analysis of ImmunityBio, Inc. (NASDAQ: IBRX) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of B+, ImmunityBio, Inc.'s NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.

The current technical analysis of IBRX on the NASDAQ shows an RSI of 70.23, suggesting the stock is in a an overbought condition. Our forecasting models predict a 12-month price target of $7.34 for the NASDAQ listing.

Key metrics behind ImmunityBio, Inc.'s NASDAQ-traded stock include a P/E ratio of -10.40 and a market capitalization of 10.8B. Combined with our AI analysis, these give both institutional and retail investors a clear view of IBRX on the NASDAQ.

Price Performance (NASDAQ: IBRX)

1-Day Change
10.83%
5-Day Change
17.41%
1-Month Change
29.37%
3-Month Change
8.95%
6-Month Change
40.89%
Year-to-Date (YTD) Change
419.44%
1-Year Change
311.40%
3-Year Change
572.22%
5-Year Change
4.52%
All-Time (Max) Change
-70.31%

Contact Information

https://immunitybio.com
858 633 0300
3530 John Hopkins Court, San Diego, CA, 92121

Company Facts

6,880 Employees
IPO DateJul 28, 2015
CountryUS
Actively Trading

Frequently Asked Questions